Securian Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.43M Sell
32,954
-682
-2% -$89.9K 0.16% 86
2026
Q1
$4.69M Sell
33,636
-100
-0.3% -$14K 0.19% 76
2025
Q4
$4.14M Sell
33,736
-26,187
-44% -$3.18M 0.16% 93
2025
Q3
$6.65M Sell
59,923
-5,084
-8% -$578K 0.18% 99
2025
Q2
$7.21M Sell
65,007
-941
-1% -$100K 0.21% 87
2025
Q1
$7.39M Sell
65,948
-1,033
-2% -$107K 0.22% 80
2024
Q4
$6.19M Sell
66,981
-1,877
-3% -$169K 0.18% 98
2024
Q3
$5.77M Sell
68,858
-2,779
-4% -$212K 0.17% 110
2024
Q2
$4.92M Sell
71,637
-1,751
-2% -$117K 0.14% 124
2024
Q1
$5.38M Sell
73,388
-5,488
-7% -$422K 0.16% 120
2023
Q4
$6.39M Sell
78,876
-10,539
-12% -$820K 0.18% 102
2023
Q3
$6.7M Sell
89,415
-15,232
-15% -$1.17M 0.2% 95
2023
Q2
$8.07M Sell
104,647
-1,209
-1% -$96.4K 0.21% 98
2023
Q1
$8.78M Sell
105,856
-175
-0.2% -$14.5K 0.23% 88
2022
Q4
$9.1M Buy
106,031
+3,883
+4% +$307K 0.25% 83
2022
Q3
$6.3M Buy
102,148
+449
+0.4% +$28.3K 0.19% 99
2022
Q2
$6.29M Sell
101,699
-513
-0.5% -$31.8K 0.15% 143
2022
Q1
$6.08M Sell
102,212
-1,466
-1% -$93.7K 0.12% 176
2021
Q4
$7.53M Sell
103,678
-903
-0.9% -$62.2K 0.14% 157
2021
Q3
$7.3M Sell
104,581
-1,192
-1% -$83.7K 0.15% 150
2021
Q2
$7.28M Sell
105,773
-747
-0.7% -$49.9K 0.15% 153
2021
Q1
$6.88M Sell
106,520
-3,380
-3% -$218K 0.15% 155
2020
Q4
$6.4M Sell
109,900
-4,240
-4% -$256K 0.14% 157
2020
Q3
$7.21M Sell
114,140
-1,173
-1% -$81.3K 0.17% 134
2020
Q2
$8.87M Sell
115,313
-8,476
-7% -$650K 0.23% 107
2020
Q1
$9.25M Sell
123,789
-2,099
-2% -$145K 0.26% 95
2019
Q4
$8.18M Sell
125,888
-3,728
-3% -$243K 0.18% 136
2019
Q3
$8.21M Sell
129,616
-1,502
-1% -$98.2K 0.19% 132
2019
Q2
$8.86M Buy
131,118
+589
+0.5% +$38.7K 0.21% 120
2019
Q1
$8.49M Sell
130,529
-499
-0.4% -$33.2K 0.2% 121
2018
Q4
$8.2M Sell
131,028
-1,566
-1% -$109K 0.22% 112
2018
Q3
$10.2M Sell
132,594
-350
-0.3% -$26.4K 0.24% 100
2018
Q2
$9.42M Sell
132,944
-407
-0.3% -$28.7K 0.23% 102
2018
Q1
$10.1M Buy
133,351
+1
+0% +$79 0.26% 94
2017
Q4
$9.55M Buy
133,350
+708
+0.5% +$53.8K 0.24% 103
2017
Q3
$10.7M Buy
132,642
+785
+0.6% +$60K 0.28% 90
2017
Q2
$9.33M Buy
131,857
+189
+0.1% +$12.6K 0.25% 95
2017
Q1
$8.94M Sell
131,668
-829
-0.6% -$58.3K 0.24% 96
2016
Q4
$9.49M Buy
132,497
+671
+0.5% +$49.9K 0.25% 102
2016
Q3
$10.4M Sell
131,826
-6
-0% -$487 0.28% 90
2016
Q2
$11M Sell
131,832
-2,145
-2% -$190K 0.31% 84
2016
Q1
$12.3M Sell
133,977
-6,035
-4% -$544K 0.35% 72
2015
Q4
$14.2M Buy
140,012
+2,109
+2% +$219K 0.42% 57
2015
Q3
$13.5M Sell
137,903
-1,394
-1% -$155K 0.44% 51
2015
Q2
$16.3M Buy
139,297
+94
+0.1% +$10.3K 0.51% 40
2015
Q1
$13.7M Buy
139,203
+2,563
+2% +$260K 0.4% 56
2014
Q4
$12.9M Buy
136,640
+3,045
+2% +$315K 0.4% 59
2014
Q3
$14.2M Sell
133,595
-2,858
-2% -$280K 0.48% 50
2014
Q2
$11.3M Sell
136,453
-250
-0.2% -$19.5K 0.38% 63
2014
Q1
$9.69M Buy
136,703
+512
+0.4% +$40.2K 0.35% 68
2013
Q4
$10.2M Buy
136,191
+483
+0.4% +$33.6K 0.39% 64
2013
Q3
$8.53M Buy
135,708
+2,474
+2% +$148K 0.34% 73
2013
Q2
$6.82M Buy
+133,234
New +$6.94M 0.28% 82

Other funds holding GILD

Securian Asset Management's GILD Position: Q2 2026 in Review

Securian Asset Management reduced its Gilead Sciences (GILD) stake by 2% in Q2 2026, selling an estimated $89.9K and leaving 32,954 shares worth $4.43M. The position accounts for 0.16% of the portfolio, ranked #86.

Securian Asset Management first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.3M in Q2 2015. 610 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Securian Asset Management held 32,954 shares of Gilead Sciences worth $4.43M as of Q2 2026.
  • Securian Asset Management sold 682 Gilead Sciences shares in Q2 2026, an estimated $89.9K.
  • Gilead Sciences made up 0.16% of Securian Asset Management's portfolio in Q2 2026, its #86 holding.
  • Securian Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Securian Asset Management's Gilead Sciences position peaked at $16.3M in Q2 2015.
  • 610 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Securian Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.